These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34672933)

  • 1. Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Parmar A; Qazi AA; Stundzia A; Sim HW; Lewin J; Metser U; O'Malley M; Hansen AR
    Can Urol Assoc J; 2022 Mar; 16(3):E113-E119. PubMed ID: 34672933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Hepburn AC; Lazzarini N; Veeratterapillay R; Wilson L; Bacardit J; Heer R
    Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics-based model for predicting pathological complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Choi SJ; Park KJ; Heo C; Park BW; Kim M; Kim JK
    Clin Radiol; 2021 Aug; 76(8):627.e13-627.e21. PubMed ID: 33762138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy.
    Zhang X; Wang Y; Zhang J; Zhang L; Wang S; Chen Y
    Front Oncol; 2022; 12():878499. PubMed ID: 35646654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study.
    Yu Y; He Z; Ouyang J; Tan Y; Chen Y; Gu Y; Mao L; Ren W; Wang J; Lin L; Wu Z; Liu J; Ou Q; Hu Q; Li A; Chen K; Li C; Lu N; Li X; Su F; Liu Q; Xie C; Yao H
    EBioMedicine; 2021 Jul; 69():103460. PubMed ID: 34233259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of
    Yang Z; Shen Z; Jin D; Zhang N; Wang Y; Lei W; Zhang Z; Chen H; Naz F; Xu L; Wang L; Wang S; Su X; Yu C; Li C
    J Clin Transl Res; 2021 Jun; 7(3):386-413. PubMed ID: 34239995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma.
    Malone ER; Sim HW; Stundzia A; Pierre S; Metser U; O'Malley M; Sacher AG; Sridhar SS; Hansen AR
    Can Urol Assoc J; 2022 Feb; 16(2):E94-E101. PubMed ID: 34582343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
    Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
    J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Mansour AM; Soloway MS; Eldefrawy A; Singal R; Joshi S; Manoharan M
    Can J Urol; 2015 Apr; 22(2):7690-7. PubMed ID: 25891331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-based radiomics signature for pretreatment prediction of pathological response to neoadjuvant chemotherapy in osteosarcoma: a multicenter study.
    Chen H; Zhang X; Wang X; Quan X; Deng Y; Lu M; Wei Q; Ye Q; Zhou Q; Xiang Z; Liang C; Yang W; Zhao Y
    Eur Radiol; 2021 Oct; 31(10):7913-7924. PubMed ID: 33825032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Kozikowski M; Suarez-Ibarrola R; Osiecki R; Bilski K; Gratzke C; Shariat SF; Miernik A; Dobruch J
    Eur Urol Focus; 2022 May; 8(3):728-738. PubMed ID: 34099417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.